NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · page 24 of 30
The slide highlights rapid adoption compared to Saxenda and notes supply chain issues impacting Q4'21 and H1'22.
Regulatory filing · competitive_analysis · quantify_opportunity · overcrowded density
Slide locked Sign in to view
Slide schematic 7/7
callout 2/2 chart 1/1 legend 1/1 paragraph 1/1 source-note 1/1 title 1/1
Components 7
primary primary bar-vertical legend paragraph source-note headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.